AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 29, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced the presentation of new preclinical data for its lead asset, AP402, at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California.